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Using exome sequencing, we identified a p.R191Q
amino acid change in the valosin-containing protein
(VCP) gene in an Italian family with autosomal domi-
nantly inherited amyotrophic lateral sclerosis (ALS).
Mutations in VCP have previously been identified
in families with Inclusion Body Myopathy, Paget
disease, and Frontotemporal Dementia (IBMPFD).
Screening of VCP in a cohort of 210 familial ALS
cases and 78 autopsy-proven ALS cases identified
four additional mutations including a p.R155H muta-
tion in a pathologically proven case of ALS. VCP
protein is essential for maturation of ubiquitin-con-
taining autophagosomes, and mutant VCP toxicity
is partially mediated through its effect on TDP-43protein, a major constituent of ubiquitin inclusions
that neuropathologically characterize ALS. Our data
broaden the phenotype of IBMPFD to include motor
neuron degeneration, suggest that VCP mutations
may account for 1%–2% of familial ALS, and pro-
vide evidence directly implicating defects in the ubiq-
uitination/protein degradation pathway inmotor neu-
ron degeneration.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease clinically characterized by upper and lower motor
neuron dysfunction resulting in rapidly progressive paralysis
and death from respiratory failure. The pathological hallmarks
of the disease include pallor of the corticospinal tract due toNeuron 68, 857–864, December 9, 2010 ª2010 Elsevier Inc. 857
Figure 1. Pedigrees of Patients with VCP Mutations
(A–E) Pedigrees of patients with VCP mutations. Mutant alleles are indicated
by mt, whereas wild-type alleles are indicated by wt. Probands are indicated
by arrows. Sex of the pedigree members is obscured to protect privacy. Pedi-
grees of the familial samples from the NINDS repository at Coriell have been
constructed based on available family history information from the Coriell web-
site (http://www.coriell.org/).
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VCP Mutations Are a Cause of Familial ALSloss of motor neurons, the presence of ubiquitin-positive inclu-
sions within survivingmotor neurons, and the deposition of path-
ological TDP-43 aggregates (Neumann et al., 2006). Median
survival is 3 years from symptom onset, reflecting the devas-
tating nature of the disease and the lack of effective disease-
modifying therapies for this disorder.
The identification of genes underlying rare familial forms of
ALS has had significant impact on our understanding of the
molecular mechanisms underlying typical ALS (Rowland and
Shneider, 2001). Much of the ongoing molecular biology work
in the ALS field is based on the discovery of mutations in genes
encoding SOD1, TDP-43, and FUS (Kwiatkowski et al., 2009;
Rosen et al., 1993; Sreedharan et al., 2008; Vance et al., 2009).
Each new gene implicated in the etiology of ALS provides funda-
mental insights into the pathogenesis of motor neuron degener-
ation and facilitates diseasemodeling and the design and testing
of targeted therapeutics; hence, there is much interest in the
identification of novel genetic mutations.
Population-based epidemiological studies estimate that
approximately 5% of ALS cases are familial in nature (Chio`
et al., 2008). Of these, approximately 15% are caused by muta-
tions in the SOD1 gene (Chio` et al., 2008), and a further 3%–4%
of cases are due to pathogenic variants in either the TDP-43 or
FUS gene (Kabashi et al., 2008; Chio` et al., 2009; Mackenzie
et al., 2010). Linkage and positional cloning studies aimed at
finding additional familial ALS genes have been complicated
by a lack of samples from large, multigenerational families,
mainly due to the dramatically shortened lifespan associated
with the diagnosis.
Whole-exome sequencing is a new technique that exploits the
massively parallel sequencing capabilities of next-generation
platforms to rapidly identify rare variants in the 1% of the
genome that codes for proteins. The power of exome
sequencing stems from the fact that the majority of monogenic
diseases arise from mutations within this protein-coding portion
of the genome, and the ability of this technology to find new
causative genes has already been demonstrated (Choi et al.,
2009; Ng et al., 2009, 2010). Furthermore, whole-exome
sequencing is now a realistic strategy for detecting pathogenic
variants in small families where linkage analysis would not be
possible due to a shortage of DNA samples from affected
individuals.
In this report, we describe exome sequencing of a family
with an autosomal dominant ALS phenotype, in which SOD1,
TDP-43, and FUS mutations were previously excluded, in an
attempt to identify the underlying genetic lesion responsible for
disease.
RESULTS
Description of the ITALS#1 Pedigree
We studied a four-generation Italian family (ITALS#1) in which
four individuals had been diagnosed with ALS. The pedigree of
this family is shown in Figure 1A, and the clinical features are
detailed in the Supplemental Information (available online) and
are summarized in Table 1. Briefly, all four patients with ALS pre-
sented with limb-onset motor neuron symptoms (Figure 1A, indi-
viduals III:4, III:8, III:12, IV:1). A parent of the proband (II:5) died at858 Neuron 68, 857–864, December 9, 2010 ª2010 Elsevier Inc.age 58 with dementia, parkinsonism, Paget disease, and upper
limb muscle weakness, and a sibling of this individual (II:4)
used a wheelchair prior to death at age 51 from respiratory
failure. The clinical course of the four ALS patients was charac-
terized by unequivocal upper and lower motor signs affecting
all four limbs and bulbar musculature resulting in progressive
quadriparesis and disability. Neuropsychological testing of indi-
vidual III:12 performed within 1 year of symptom onset was
suggestive of mild frontal lobe dysfunction. Nerve conduction
studies and electromyography in each case demonstrated wide-
spread ongoing denervation and chronic reinnervation changes
consistent with ALS. Alkaline phosphatase was within normal
limits, thereby excluding the diagnosis of concomitant Paget
disease. DNA samples were available from three individuals of
generations III and IV who had been diagnosed with ALS by
neurologists specializing in ALS (A. Chio` and J.M.). Autopsy
Table 1. VCPMutations in ALS Cases with Onset and Disease Duration Data
Pedigreea
Individual
ID Mutationb Diagnosis
Age at
Onset
Site of
Onset
Cognitive
Impairment
Disease Duration
from Onset
(Vital Status)
ALP
(U/L)
CPK
(U/L)
ITALS#1 III:4 p.R191Q
c.961G > Ac
ALS 51 upper limb no impairment;
not formally tested
ventilated at 11 months
(died at 29 months)
normal normal
III:8 p.R191Q
c.961G > A
ALS 53 upper and
lower limbs
no impairment
on formal testing
ventilated at
34 months (alive)
normal normal
III:12 p.R191Q
c.961G > A
ALS-FTD 50 lower limb impaired on
formal testing
alive at 4.5 years normal 385
IV:1 p.R191Q
c.961G > A
ALS 37 lower limb no impairment
on formal testing
alive at 4 years normal 500–900
USALS#1 III:4 p.R159G
c.864C > G
ALS-FTD 53 lower limb impaired on
formal testing
ventilated at
24 months (alive)d
no data no data
III:6 p.R159G
c.864C > G
ALS 46 lower limb no impairment;
not formally tested
died after 5 years elevated no data
Coriell#1 ND13215 p.R191Q
c.961G > A
ALS 42 lower limb no impairment;
not formally tested
alive at 12 years no data no data
Coriell#2 ND09607 p.D592N
c.2163G > A
ALS 52 bulbar no impairment;
not formally tested
died within 1 year no data no data
UP731 III:1e c.853G > A
p.R155H
ALS 53 upper limb no impairment;
not formally tested
died at 39 months normal normal
ALP, alkaline phosphatase;CPK, creatine phosphokinase. See also Table S2 for demographics and clinical details of ALS cases and controls screened
for VCP mutations.
a See Figure 1 for pedigrees.
bNucleotide position is based on NM_007126.3, and amino acid numbering is based on NP_009057.1.
c III:4 of family ITALS#1 is an obligate carrier of this mutation.
dRespiratory failure hastened by coexisting pulmonary disease.
e III:1 of family UP731 is an obligate carrier of this mutation.
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pedigree.
Exome Sequencing of the ITALS#1 Pedigree
Exome sequencing was performed on DNA obtained from two
affected members of the ITALS#1 family (Figure 1A, ITALS#1,
III:12, and IV:1) using SureSelect Exome target enrichment
technology followed by paired-end sequencing on a Genome
Analyzer IIx. This generated 3.48 gigabases of alignable
sequence data for patient III:12 (median read depth = 40, base
pairs with >10 reads = 79.9%) and 3.53 gigabases for patient
IV:1 (median read depth = 37, base pairs with >10 reads =
76.1%). The same portion of the exome was sequenced in
both patients (r2 = 0.92 comparing the number of reads per tar-
geted sequence [bait] in each sample). After filtering, there were
75 heterozygous coding variants and 13 heterozygous coding
indels that had not previously been identified as variants in
the 1000 Genomes or dbSNP databases, and which were
shared by both patients (Figure 2). Sanger sequencing of these
variants in an additional affected member (III:8) reduced
this list to 24 variants and nine indels (see Table S1 available
online). Of these, only four variants were within the 18 genomic
regions with a LOD score greater than zero based on linkage
analysis of the ITALS#1 pedigree (see Figure S1 available
online; Sobreira et al., 2010), were not present in the exome
data of 200 neurologically normal control samples, andwere pre-dicted to be damaging to protein structure using SIFT software
analysis.
Each of these variants segregated with disease within the
family, and therefore were plausible candidates for the genetic
defect responsible for disease. Within this list, we identified
a c.961G > A nucleotide change that resulted in a p.R191Q
amino acid change in the VCP gene. This particular mutation
has been previously described as the cause of an unusual
syndrome characterized clinically by the triad of Inclusion Body
Myopathy with early-onset Paget disease of the bone and Fron-
totemporal Dementia (IBMPFD) (Watts et al., 2004), and charac-
terized pathologically by the presence of TDP-43 staining ubiq-
uitin inclusions in muscle and frontal cortex neurons (Ju and
Weihl, 2010). Since ALS is also characterized by the deposition
of TDP-43 inclusions (Neumann et al., 2006), and the identified
mutations are known to alter VCP structure and impair VCP
function and to be pathogenic in humans (Custer et al., 2010;
Ferna´ndez-Sa´iz and Buchberger, 2010; Ju et al., 2009; Ritson
et al., 2010; Tang et al., 2010; Tresse et al., 2010; Watts et al.,
2004), we postulated that mutations in the VCP gene could
also give rise to an ALS phenotype.
Mutational Screening of VCP in Additional Familial
ALS Samples
To test our hypothesis and to establish the frequency of VCP
mutations in ALS, we sequenced 210 cases from unrelatedNeuron 68, 857–864, December 9, 2010 ª2010 Elsevier Inc. 859
Figure 2. Filters Applied to Variants and Indels Detected by
Exome Sequencing in Affected Individuals of the ITALS#1 Pedigree
Regions with LOD score greater than zero were based on linkage analysis of
ITALS#1 pedigree (see also Figure S1). Variants that were found in exome
data of 200 neurologically normal control subjects were filtered. Prediction
of effect of variant on protein function was based on SIFT analysis (http://
sift.jcvi.org/).
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additional mutations in five individuals diagnosed with ALS
(Table 1). None of thesemutations were found in 569 U.S. control
samples, in 636 Italian control samples, in 364 African and Asian
samples that are part of the Human Gene Diversity Panel
(HGDP), or in either the dbSNP or 1000 Genomes databases,
and all of them affected amino acids that were highly conserved
across species (Figure 3).
The additional mutations included a p.R159G mutation that
segregated with disease in a U.S. family whose variousmembers
have carried diagnoses of ALS, frontotemporal dementia (FTD),
and Paget disease (see Figure 1B for pedigree structure and
Supplemental Information for clinical description). Though to
our knowledge mutation p.R159G has not been previously iden-
tified, different mutations involving the same codon (p.R159H
and p.R159C) have been previously described as a cause of
IBMPFD (Daroszewska and Ralston, 2005; Kimonis et al.,
2008a; Schro¨der et al., 2005). We also detected a second
example of the p.R191Q mutation found in the ITALS#1 family
(Figure 1C). This patient (ND13215) carried the same 199.8 kb
haplotype across the VCP locus as affected members of the
ITALS#1 pedigree, and identity-by-descent analysis based on
genome-wide genotyping data confirmed that he was cryptically
related to the Italian kindred (PI_hat between ND13215 and indi-860 Neuron 68, 857–864, December 9, 2010 ª2010 Elsevier Inc.vidual IV:4 of ITALS#1 = 0.251, indicating that these cases
were second degree relatives). A novel p.D592N mutation was
detected in a separate ALS family (Figure 1D). Protein structure
analysis revealed that residue D592 is directly adjacent to the
central pore formed by the VCP hexamer (see Figure S2).
Finally, we identified a p.R155H mutation in a large, multigen-
erational family with IBMPFD (Watts et al., 2004), in which an
obligate carrier of the VCP mutation (Figure 1C, III:1) had
been clinically diagnosed with ALS without evidence of IBM
or Paget disease. Autopsy revealed loss of brainstem and
spinal cord motor neurons with Bunina bodies in surviving ante-
rior horn cells and TDP-43 immunostaining consistent with the
diagnosis of ALS (Figure 4, and Supplemental Experimental
Procedures for detailed clinical summary and pathological
description).
The clinical phenotypes of the patients carrying VCP muta-
tions are summarized in Table 1. Consistent with VCP as
a known cause of frontal lobe dysfunction, at least one member
of the ITALS#1 family and two affected members of the family
carrying the p.R159G mutation were diagnosed with significant
cognitive impairment. Apart from the deceased parent of
the proband in the ITALS#1 family and an affected member of
the USALS#1 pedigree, none of the other patients reported
personal or family history of bone disease or myopathy. Histo-
logical examination of a tibialis anterior muscle biopsy from
patient III:4 of family ITALS#1 was consistent with denervation
and reinnervation, and did not show pathological features of
IBM (see Figure S3). At least five patients with VCP mutations
had a rapidly progressive disease course in that they either
died or required mechanical ventilation within 3 years of
symptom onset.
DISCUSSION
In this paper, we used whole-exome sequencing to identify
a pathogenic VCP variant in an autosomal dominant Italian family
with an ALS phenotype, and subsequently found that VCPmuta-
tions were present in1%–2%of our large cohort of familial ALS
cases from unrelated families. Though the frequency of VCP
mutations in familial ALS will have to be confirmed in indepen-
dent cohorts, this mutational frequency is comparable to that
reported for TDP-43 and FUS mutations (Kabashi et al., 2008;
Chio` et al., 2009; Mackenzie et al., 2010), highlighting the relative
significance of this gene as a cause of familial ALS. Furthermore,
our study shows that this new genomics technique can success-
fully be applied to find causative mutations in autosomal domi-
nant neurodegenerative disease, where DNA is available from
such a limited number of cases that linkage and positional
cloning would not be feasible.
Althoughwe have nominated VCP as the causativemutation in
our Italian family, it remains possible that one of the other three
shared variants identified by the whole-exome sequencing
process is the true cause of disease. In addition, although the
depth of sequencing coverage in our samples was adequate
to identify several thousands of variants, other mutations
may have been missed, either due to stochastic variations in
sequence capture or coverage, or because they lie outside of
coding regions.
Figure 3. Distribution of VCP Mutations Detected in Familial ALS Patients
An ideogram of chromosome 9 is shown at the top. The 17 exons of VCP are numbered. Mutations detected in familial ALS cases are indicated in red, whereas
mutations previously described to cause IBMPFD are shown in black. Corresponding chromatograms showingmutant and wild-type alleles are as indicated, and
conservation of amino acid residue across species is highlighted at the bottom (generated using the ClustalW2 online tool, http://www.ebi.ac.uk/clustalw/). See
also Figure S2 for location of mutations on VCP protein structure.
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the pathogenicity of the p.R191Q VCP variant in our family.
First, the p.R191Q variant was found in three affected individ-
uals within the ITALS#1 family, and a fourth affected member
(patient III:4) was an obligate carrier. Second, we did not find
this mutation in the dbSNP database, in the 1000 Genomes
project database, or in 1569 control subjects (3138 control
chromosomes) sequenced in our laboratory. Third, the same
amino acid change has been previously described as patho-
genic in two large, multigenerational IBMPFD families (Watts
et al., 2004; S. Spina et al., 2008, FASEB J., abstract). Fourth,
we found several other instances of VCP mutations in familial
ALS cases. These included a second example of the same
p.R191Q variant in an apparently unrelated familial case
(Coriell#1) that carried a 199.8 kb haplotype across the VCP
locus identical to those of affected members of the ITALS#1
pedigree, suggesting that these individuals shared a common
ancestor. In addition to these genetic data, ALS and IBMPFD
share a common pathology in that both conditions lead to
the deposition of ubiquitin-positive TDP-43 inclusions indiverse tissue types including neurons of the frontal cortex
(Ince et al., 1998; Weihl et al., 2009). Furthermore, a missense
mutation in vacuolar protein sorting 54, the mouse homolog of
VCP, is responsible for motor neuron degeneration in the
wobbler mouse, an animal model of ALS (Schmitt-John et al.,
2005).
Although it may be retrospectively argued that VCP was an
obvious candidate gene for the causation of ALS, there are no
prior publications of mutational screening of this gene in ALS
patients. Furthermore, weakness in affected individuals carrying
VCP mutations has been uniformly ascribed to muscle involve-
ment by IBM, even when their clinical features were clearly
consistent with motor neuron degeneration (Kimonis et al.,
2008b; Kumar et al., 2010). Indeed, until now, a diagnosis of
ALS in patients carrying VCPmutationswas regularly considered
to be erroneous (Kimonis et al., 2008a; Weihl et al., 2009). It is
noteworthy that the samples used in our study for exome
sequencing and subsequent mutational screening of VCP were
selected because they had been diagnosed as having familial
ALS. The presence of Paget disease and FTD in the ITALS#1Neuron 68, 857–864, December 9, 2010 ª2010 Elsevier Inc. 861
Figure 4. Histopathological Images from Autopsy Tissue, Family
UP731, Individual III:1
(A) Haematoxylin-eosin (H&E) stained low-power view (1003) of a lumbar spinal
cord section demonstrates extensive motor neuron loss in the anterior horn,
with a few remaining motor neurons (arrow). (B) Motor neurons from the hypo-
glossal nucleus in the medulla with abundant round eosinophilic cytoplasmic
inclusions consistent with Bunina bodies (arrows), H&E, 2003. (C and D)
2003 and 4003, respectively: TDP-43 immunohistochemistry on the hypo-
glossal nucleus shows TDP-43 positive punctate cytoplasmic inclusions with
concomitant loss of nuclear stain in two motor neurons (arrows). Normal
nuclear staining ispreserved in the surrounding normal cells.Of note, additional
tissue was not available from this autopsy. The current images were generated
by removing the coverslip from selected old slides, followed by destaining
and processing for TDP-43 immunohistochemistry. See also Figure S3 for
histopathological images of a muscle biopsy from patient III:4 of the ITALS#1
family.
Neuron
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mutations were discovered.
In contrast to the previous publications in which motor neuron
degeneration was misdiagnosed, our data clearly indicate that
mutations in the VCP gene can be associated with a classical
ALS phenotype. In this study, all of the cases in which we found
VCP mutations displayed upper and lower motor neuron signs
consistent with a diagnosis of ALS on the basis of the El
Escorial diagnostic criteria, which are known to be highly
specific for ALS (Chaudhuri et al., 1995). Apart from a single
member of the USALS#1 family who developed Paget disease
prior to onset of muscle weakness, none of the analyzed cases
displayed atypical features, such as biochemical or radio-
graphic signs of bone disease. EMG studies in each patient
revealed widespread ongoing denervation and chronic reinner-
vation changes, which are the pathognomonic neurophysiolog-
ical features of ALS. Two of the affected individuals in the
original Italian family followed a rapidly progressive course,
requiring mechanical ventilation within 2 years of symptom
onset. Such rapid progression is not seen in IBM patients,
where life expectancy is typically not significantly shortened
(Amato and Barohn, 2009). Finally, autopsy data from an
affected individual carrying the p.R155H mutation demon-
strated brainstem and spinal cord motor neuron loss in the862 Neuron 68, 857–864, December 9, 2010 ª2010 Elsevier Inc.presence of TDP-43 staining and Bunina bodies, thereby path-
ologically confirming the clinical diagnosis of ALS (Ince et al.,
1998; Neumann et al., 2006).
Despite these clinical data supporting the presence of fulmi-
nant motor neuron degeneration, the possibility that these
patients had coexisting IBM cannot be excluded. Muscle
involvement in the pathogenesis and progression of ALS has
long been debated (Abmayr andWeydt, 2005), and VCP-associ-
ated disease may represent an instance in which muscle and
nerve are simultaneously affected, thus offering an opportunity
to dissect this relationship. At the very least, our data widen
the clinical symptomatology associated with VCP mutations to
include an ALS phenotype, and suggest that familial ALS
patients should be monitored for features of IBM and osteoclast
dysfunction (for example, by screening for elevated serum alka-
line phosphatase).
VCP is a highly conserved AAA+-ATPase that mediates ubiq-
uitin-dependent extraction of substrates from multiprotein
complexes for subsequent recycling or degradation by the
proteasome. Through this activity, VCP regulates a variety of
cellular functions including cell signaling, cell cycling, organelle
biogenesis, autophagy, and certain aspects of proteostasis.
Mutant VCP toxicity is mediated in part through altered TDP-
43 metabolism (Ritson et al., 2010). TDP-43 pathology has
been observed in spinal cord motor neurons of mouse models
of VCP mutations (Custer et al., 2010), and mutant VCP expres-
sion leads to redistribution of TDP-43 from the nucleus to the
cytoplasm in vitro and in vivo (Custer et al., 2010; Gitcho et al.,
2009; Ritson et al., 2010).
Despite this, the molecular mechanisms by whichmutations in
the VCP gene cause motor neuron degeneration and the various
features of the IBMPFD syndrome are not clear. It is known
that VCP is essential for maturation of ubiquitin-containing
autophagosomes, and that disease-causing mutations in VCP
impair this process (Alexandru et al., 2008; Halawani and
Latterich, 2006; Ju et al., 2009; Ju andWeihl, 2010). It is plausible
that these mutations disrupt its protein removal function, leading
to the accumulation of degraded proteins observed as ubiquiti-
nated inclusions within the cell. It is noteworthy that the
known mutations of VCP predominantly cluster within the cleft
that separates the D1 and N domains of the protein (see Fig-
ure S2), and may interfere with VCP function by impairing the
relative movement of these domains that occurs in response to
ATP hydrolysis (Dai and Li, 2001; Tang et al., 2010). Our data
provide evidence directly implicating defects in the cellular
machinery of the ubiquitination/protein degradation pathway in
motor neuron degeneration. Additional studies will be required
to confirm this putative pathophysiological function of mutant
VCP, and to determine if the location of the mutations within
the VCP protein influence which tissues are affected by ubiquitin
deposition and account for the heterogeneous clinical symptom-
atology known to exist within this syndrome (van der Zee
et al., 2009).
In summary, our data demonstrate the utility of exome
sequencing in determining the genetic causes of familial neuro-
degeneration, and indicate that mutations of the VCP gene are
a cause of familial ALS. Another interpretation of our data, which
is compatible with the conclusion that mutations in VCP are
Neuron
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IBMPFD is broader than previously recognized and extends to
include ALS. Our study also potentially widens the clinical spec-
trum associated with ALS to include bone dysfunction and
myopathy, and provides further insight into the importance of
cellular protein degradation pathways in this fatal neurodegener-
ative disease.
EXPERIMENTAL PROCEDURES
Patient Samples
Exome sequencing was performed on a four-generation Italian family in which
four individuals had been diagnosed with ALS (ITALS#1, Figure 1A). The clin-
ical details of this family are summarized in Table 1 and a detailed description is
available in the Supplemental Information.
For subsequent mutational screening of VCP, an additional 210 DNA
samples were obtained from affected individuals in unrelated ALS families
(169 US cases and 41 Italian cases), and from 78 ALS cases for which autopsy
material was available. Control samples consisted of 569 neurologically
normal U.S. individuals obtained from the NINDS repository at the Coriell
Cell Repositories (equivalent to 1138 control chromosomes), and 636 neuro-
logically normal Italian individuals (1272 chromosomes). An additional series
of 364 anonymous African and Asian samples that are part of the HGDP
(Cann et al., 2002) were included in the mutational analysis as controls to
evaluate the genetic variability of VCP in non-Caucasian populations.
Demographics and clinical features of these samples are described in the
Supplemental Information and are summarized in Table S2. Appropriate
institutional review boards approved the study.
Exome Sequencing
DNA from affected individuals III:12 and IV:1 of the ITALS#1 family was en-
riched using SureSelect Exome target enrichment technology according to
the manufacturer’s protocol (version 1.0, Agilent, CA). The enriched DNA
was paired-end sequenced on aGenomeAnalyzer IIx (Illumina, CA). Sequence
alignment and variant calling were performed against the reference human
genome (UCSC hg 18) using the Genome Analysis Toolkit (http://www.
broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_Toolkit). PCR
duplicates were removed prior to variant calling using Picard software
(http://picard.sourceforge.net/index.shtml). Based on the hypothesis that
the mutation underlying this rare familial disease was not present in the
general population, SNPs identified in the 1000 Genomes project (www.
1000genomes.org/) or in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/,
Build 131) were removed. We then excluded variants that were not shared
by both patients. Next, synonymous changes were identified and filtered
from the variant list using SIFT software (version 4.0, http://sift.jcvi.org/).
Sanger sequencing using customized primers was performed to determine
the presence of the remaining variants in the other affected member of the
ITALS#1 family (patient III:8). As an additional step, variants and indels de-
tected in the ITALS#1 family were filtered against exome data generated for
200 neurologically normal control subjects.
Linkage Analysis
Linkage analysis was performed on the ITALS#1 pedigree by genotyping four
family members (Figure 1A; individuals III:6, III:8, III:12, and IV:1) using Illumina
Human660W-Quad genotyping arrays. We selected 2% of the genotyped
SNPs (12,092 autosomal SNPs), and used them for parametric linkage in the
Merlin linkage software assuming a dominant model (Abecasis et al., 2002;
Sobreira et al., 2010). Linkage analysis identified 18 regions across the auto-
somes with a LOD score greater than zero (see Figure S1) (Abecasis et al.,
2002; Sobreira et al., 2010).
Mutational Screening
All 17 exons and flanking introns of the VCP gene (NM_007126.3) were
sequenced using the Big-Dye Terminator v3.1 chemistry (ABI, CA), run on an
ABI 3730xl analyzer, and analyzed using Sequencer software version 4.2(Gene Codes, MI). PCR primers and conditions are listed in Table S3. Muta-
tions of ANG, DCTN1, FUS, OPTN, SETX, SOD1, and TDP-43 were similarly
excluded in cases carrying VCP mutations.
Haplotype Analysis
Haplotypes across the VCP locus in the two unrelated families carrying the
p.R191Q mutation were compared by genotyping individuals IV:1 from the
ITALS#1 pedigree and ND13215 from the Coriell#1 pedigree using Illumina
Human660W-Quad genotyping arrays, and analyzing the resulting SNP data
using Haploview 4.2 (Barrett et al., 2005). The degree of relatedness of the
samples (quantified as the PI_hat metric) was determined using identity-by-
descent algorithm within the PLINK software (Purcell et al., 2007).SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes three figures, three tables,
Supplemental Experimental Procedures, and list of additional members of
the ITALSGEN Consortium and can be found with this article online at
doi:10.1016/j.neuron.2010.11.036.
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